Log In
BCIQ
Print this Print this
 

Abasaglar, Basaglar, insulin glargine (LY2963016) (formerly Abasria)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionBasal insulin analog
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type I and II diabetes; Treat Type I diabetes; Treat Type II diabetes
Regulatory Designation U.S. - Undisclosed Review (Treat Type I and II diabetes);
EU - Biosimilar (Treat Type I and II diabetes);
EU - Standard Review (Treat Type I and II diabetes)
PartnerBoehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$2,367.9M

$386.0M

$1,456.0M


 Deals Details
Get a free BioCentury trial today